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Dysregulated cytokine expression and signaling are
major contributors to a number of autoimmune dis-
eases. Interleukin-17A (IL-17A) and IL-6 are important
in many disorders characterized by immune self-rec-
ognition, and IL-6 is known to induce the differentia-
tion of T helper 17 (Th17) cells. Here we described
an IL-17A-triggered positive-feedback loop of IL-6
signaling, which involved the activation of the tran-
scription factors nuclear factor (NF)-kB and signal
transducer and activator of transcription 3 (STAT3)
in fibroblasts. Importantly, enhancement of this loop
caused by disruption of suppressor of cytokine
signaling 3 (SOCS3)-dependent negative regulation
of the IL-6 signal transducer gp130 contributed to
the development of arthritis. Because this mecha-
nism also enhanced experimental autoimmune en-
cephalomyelitis (EAE) in wild-type mice, it may be
a general etiologic process underlying other Th17
cell-mediated autoimmune diseases.
INTRODUCTION
Autoimmune diseases—a heterogeneous group of disorders
that are controlled by many genetic and environmental fac-
tors—are most simply defined by the presence of mediators of
autoimmunity, such as autoantibodies or autoreactive lympho-
cytes. Various complex molecular processes differentially inter-
act in each of these disease states, which often manifest with
similar symptoms, making it difficult to identify general etiologic
mechanisms (Andersson and Holmdahl, 2005; Davidson and
Diamond, 2001; Falcone and Sarvetnick, 1999; Marrack et al.,
2001; Mathis and Benoist, 2004; Wandstrat and Wakeland,
2001). A common feature among them, however, is that disease
expression depends on the activation status of the immune sys-
tem. Thus, current research is focused on identifying the mech-
anisms that result in the causative dysregulation of the immune628 Immunity 29, 628–636, October 17, 2008 ª2008 Elsevier Inc.system. For example, it is believed that inflammation is critical
for the induction of autoimmune diseases, because some auto-
immune and autoimmune-related diseases, including rheuma-
toid arthritis, are characterized by robust immune responses
that result in unresolved inflammation (Baccala et al., 2007;
Hirano, 2002; O’Shea et al., 2002).
In the immune system, CD4+ T cells serve as an important
source of proinflammatory cytokines. Interestingly, cytokines,
and in particular such proinflammatory cytokines as tumor
necrosis factor-a (TNF-a) and interleukin-6 (IL-6), are critically in-
volved in autoimmune diseases (Hirano, 2002; Ioannou and Isen-
berg, 2000; O’Shea et al., 2002). In fact, anti-TNF-a and anti-IL-6
receptor therapies have been successfully employed for a num-
ber of chronic autoimmune diseases, including rheumatoid
arthritis and Crohn’s disease (Andreakos et al., 2002; Nishimoto
and Kishimoto, 2004). Although classification of CD4+ T cells
into T helper 1 (Th1) and Th2 cells has provided a framework for
understanding the roles of various CD4+ T cell subtypes in the de-
velopment of autoimmune diseases (Glimcher and Murphy, 2000;
Mosmann and Coffman, 1989; Zhu et al., 2006), recent studies
have identified Th17 cells as a previously unknown arm of the
CD4+ T cell effector response. These cells secrete several proin-
flammatory cytokines, including IL-17A (Bettelli et al., 2007; Cua
et al., 2003; Harrington et al., 2005; Park et al., 2005; Veldhoen
et al., 2006), deficiency of which in mice results in resistance to
such autoimmune diseases as collagen-induced arthritis, exper-
imental autoimmune encephalomyelitis (EAE), and the arthritis
disorders that develop in SKG and IL-1 receptor antagonist-defi-
cient mice (Afzali et al., 2007; Bettelli et al., 2007; Hirota et al.,
2007; Iwakura and Ishigame, 2006). The development of Th17
cells requires a combination of T cell receptor (TCR) stimulation,
TGF-b, and IL-6 followed by retinoic acid-related orphan recep-
tor-gt expression via signal transducer and activator of transcrip-
tion 3 (STAT3) activation (Bettelli et al., 2007; Ivanov et al., 2006;
Nishihara et al., 2007; Veldhoen et al., 2006). Moreover, it was re-
ported that T cells serve as a source of TGF-bduring Th17 cell dif-
ferentiation (Li et al., 2007). Among these mediators, the multi-
functional cytokine IL-6 has been suggested to play a central
role in a number of diseases (Hirano, 1998; Ishihara and Hirano,
2002). Indeed, IL-6 deficiency suppresses the development of
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arthritis that develops in mice carrying a Y759F mutation in the IL-
6 receptor subunit gp130 (F759 mice), which enhances the re-
ceptor signaling (Boe et al., 1999; Campbell et al., 1991; Hirota
et al., 2007; Okuda et al., 1998; Sasai et al., 1999; Sawa et al.,
2006). Considering the requirement of IL-6 for Th17 cell develop-
ment, these results suggest that IL-6 acts upstream of IL-17A to
induce the onset of various autoimmune diseases. How IL-17A
contributes to autoimmune diseases and/or inflammation, how-
ever, has yet to be elucidated. Thus, identification of the down-
stream targets of IL-17A that directly contribute the development
of autoimmune diseases should advance our understanding of
the mechanisms underlying IL-17A-mediated diseases.
Our research has focused on IL-6 and the associated signaling
pathways. We have established several knockin mouse lines
expressing mutated variants of gp130, a transducer of IL-6
signaling (Ohtani et al., 2000), and showed that F759 mice spon-
taneously develop an rheumatoid arthritis-like disease that
depends on mature lymphocytes (Atsumi et al., 2002). Because
Y759 of gp130 is essential for the suppressor of cytokine signal-
ing 3 (SOCS3)-dependent negative regulation of gp130 signaling
(Ilangumaran et al., 2004; Yoshimura et al., 2007), IL-6- and
gp130-mediated STAT3 activation is enhanced in F759 mice.
In other words, SOCS3-mediated negative feedback is specifi-
cally defective in the gp130 signaling pathway of F759 mice.
The development of disease in the F759 mice is at least partially
dependent on IL-6 (Sawa et al., 2006). The disease severity in the
F759 mice is also accelerated in a manner dependent on IL-6 by
crossing the mice with human T cell leukemia virus 1 (HTLV-1)
p40-Tax transgenic mice in which nuclear factor (NF)-kB signal-
ing was enhanced (Ishihara et al., 2004). These results suggest
that IL-6 is one of critical factors for the disease in F759 mice.
Moreover, F759 mice develop arthritis in a manner dependent
on the homeostatic proliferation of CD4+ T cells, although the
F759 mutation is not required in T cells for the disease. Rather,
the F759 mutation in nonhematopoietic cells is essential for
IL-7-mediated CD4+ T cell homeostatic proliferation as well as
disease development (Sawa et al., 2006).
Here, we showed that IL-6 not only functioned upstream of
IL-17A but also acted as a critical downstream target of IL-17A
and, unexpectedly, that IL-17A together with IL-6 triggered
a positive-feedback loop of IL-6 expression through the activa-
tion of NF-kB and STAT3 in fibroblast cells. We showed that
blockade of the IL-6 loop significantly suppresses the develop-
ment of arthritis in F759 mice and EAE. Thus, we concluded
that IL-17A promotes autoimmune diseases by triggering a
positive-feedback loop via IL-6 induction.
RESULTS
An IL-17A-Triggered Positive-Feedback Loop
of IL-6 Expression in Fibroblasts
Because many autoimmune diseases are dependent on both
IL-17A and IL-6, and because IL-17A induces the expression
of IL-6 in fibroblasts (Yao et al., 1995), we hypothesized that
IL-6 functions not only as an inducer of Th17 cell differentiation
but also as a downstream effector of IL-17A. Moreover, both
IL-17A and IL-6 may function together during the effector phases
of autoimmune diseases. We first investigated the roles of IL-17Aand IL-6 signaling in fibroblasts because we previously used chi-
meric mice with transplanted bone-marrow cells to show that the
F759 mutation in nonhematopoietic cells but not in hematopoi-
etic cells results in spontaneous autoimmune arthritis (Sawa
et al., 2006). We prepared mouse embryonic fibroblast (MEF)
cells from WT mice. After the MEF cells were stimulated with
IL-17A in the presence or absence of IL-6, we analyzed the
expression of various target molecules of the IL-17A–NF-kB
signaling pathway, including IL-6. The expression of each of
the IL-17A–NF-kB targets tested (IL-6, keratinocyte-derived cy-
tokine [KC], and MIP2) was synergistically enhanced by IL-17A
and IL-6 (Figures 1A and 1B and Figure S1 available online).
Depleting the MEF cells of molecules involved in either IL-17A
or IL-6 signaling, such as NEMO or STAT3, respectively, showed
that IL-6 expression is completely dependent on NF-kB signaling
and that the synergistic effect of IL-17A and IL-6 on IL-6 expres-
sion was mediated by STAT3 signaling (Figures 1C and 1D).
IL-1b- and TLR ligand-triggered IL-6 expression has been re-
ported to depend on IkB-z, another target of NF-kB (Yamamoto
et al., 2004). Similarly, the expression of IkB-zwas synergistically
enhanced by IL-17A plus IL-6 in MEF cells, and this effect was
ameliorated by knocking down STAT3 expression (Figure 1E).
Furthermore, deleting IkB-z completely suppressed IL-6 expres-
sion even after treatment with IL-17A and IL-6 (Figure 1F). Con-
sistent with these results, IL-17A overexpression increased
the serum IL-6 concentration in WT animals (Figure 1G). Taken
together, the data showed that fibroblasts contain an IL-17A-
triggered positive-feedback loop of IL-6 expression, which is
mediated through NF-kB and STAT3.
Enhancement of the IL-17A-Triggered
Positive-Feedback Loop of IL-6 Expression in F759Mice
We next hypothesized that excess IL-6 signaling resulting from
an enhancement of this positive-feedback loop in fibroblasts is
involved in autoimmune diseases. To test this hypothesis, we
used F759 mice as an animal model; the IL-6–gp130-STAT3 sig-
naling pathway is specifically enhanced in these mice because of
the lack of SOCS3-dependent negative feedback. As expected,
compared to the amounts observed in WT cells, F759 MEF cells
expressed higher IL-6 and the NF-kB target KC in response to
treatment with IL-17A plus IL-6 (Figures 2A and 2B), indicating
that the IL-17A-triggered positive-feedback loop of IL-6 expres-
sion is enhanced in F759 MEF cells. Importantly, overexpression
of IL-17A resulted in a larger increase in the serum IL-6 concen-
tration in young F759 mice (2 months old and arthritis free) com-
pared with that observed in age-matched WT animals (Figures
2C). These results demonstrated that the IL-17A-triggered pos-
itive-feedback loop of IL-6 expression is enhanced in F759
mice. This conclusion was further supported by the significantly
higher serum IL-17A concentrations in older F759 mice com-
pared to young F759 or age-matched WT mice (Figure 2D), the
increased numbers of Th17 cells in older F759 mice compared
with control mice (Figure 2E), and the elevated serum IL-6
concentration observed in older F759 mice (Figure 2F). Thus,
F759 mice especially in age had an enhanced IL-17A-triggered
positive-feedback loop of IL-6 expression.
Soluble IL-6 receptor (IL-6R) has been detected in the serum
of such autoimmune-prone mice as MRL/lpr, BWF1, and BXSB
mice (Suzuki et al., 1993). We examined whether the amount ofImmunity 29, 628–636, October 17, 2008 ª2008 Elsevier Inc. 629
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concentration of soluble IL-6R age-dependently increased in
F759 mice (Figure S2A), although young F759 and age-matched
Figure 1. IL-17A-Triggered Positive-Feedback Loop of IL-6 Expres-
sion in Fibroblasts of WT Mice
(A and B) MEF cells were prepared from WT C57BL/6 mice and then stimulated
with human IL-6 + soluble IL-6R and/or IL-17A for 24 hr. The culture superna-
tant was collected and assessed with ELISAs specific for (A) IL-6 or (B)
keratinocyte-derived cytokine (KC).
(C) MEF cells derived from NEMO-deficient mice were stimulated with human
IL-6 + soluble IL-6R and/or IL-17A for 24 hr. The culture supernatant was
collected and assessed with ELISAs specific for IL-6.
(D and E) MEF cells from WT mice were transfected with siRNA specific for
STAT3 or a scrambled control. The cells were then stimulated with human
IL-6 + soluble IL-6R and/or IL-17A. The culture supernatant was collected
24 hr after stimulation and assessed with ELISAs specific for (D) IL-6 or (E)
the expression of IkB-z mRNA was calculated after 1 hr with real-time PCRs.
(F) MEF cells derived from IkB-z-deficient mice or WT controls were stimulated
with human IL-6 + soluble IL-6R and/or IL-17A for 24 hr. The culture superna-
tant was collected and assessed with ELISAs specific for IL-6.
(G) WT C57BL/6 mice (2 months old) were intravenously injected with mock or
IL-17A expression vector. Serum concentrations of IL-6 were determined with
ELISAs.
Graphs in (A)–(F) show mean ± SD of more than three independent ex-
periments. p values were calculated with Student’s t tests. **p < 0.01;
***p < 0.005; n.s., not significant.630 Immunity 29, 628–636, October 17, 2008 ª2008 Elsevier Inc.WT mice show similar amounts (data not shown). We also
showed that soluble IL-6R enhanced IL-6 production in MEF
cells in the presence of IL-6 and IL-17A (Figure S2B). Thus, sol-
uble IL-6R may play a role to IL-17A-triggered positive-feedback
loop of IL-6 expression in F759 mice with age.
IL-6 Downstream of IL-17A Is Involved
in the Development of Arthritis
We then looked for a link between the enhanced IL-17A-trig-
gered positive-feedback loop of IL-6 expression and the devel-
opment of autoimmune arthritis in the F759 mice. We first estab-
lished double mutant animals by crossing mice carrying the
Y759F mutation in gp130 with IL-17A-deficient (Il17a/) mice.
Depleting F759 mice of IL-17A significantly suppressed the
development of arthritis (Figure 3A), indicating that the arthritis
Figure 2. The IL-17A-Triggered Positive-Feedback Loop of IL-6
Expression Is Enhanced in F759 Mice
(A and B) MEF cells were prepared from F759 mice and then stimulated with
human IL-6 + soluble IL-6R and/or IL-17A for 24 hr. The culture supernatant
was collected and assessed with ELISAs specific for (A) IL-6 or (B) keratino-
cyte-derived cytokine (KC).
(C) F759 mice (2 months old) were intravenously injected with mock or IL-17A
expression vector. Serum concentrations of IL-6 were determined with ELISAs.
(D–F) Young F759 (2 months old), older F759 (10–12 months old), or control
mice were sacrificed and T cells isolated from their lymph nodes and spleens
were subjected to intracellular labeling of IL-17A. (E) The actual number of
CD4+CD44hiIL-17A+ T cells was calculated. Serum concentrations of IL-17A
(D) and IL-6 (F) were determined with ELISAs.
All graphs show mean ± SD of more than three independent experiments.
p values were calculated with Student’s t tests. *p < 0.05; **p < 0.01; ***p < 0.005.
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overexpressed IL-17A by using the hydrodynamics-based trans-
fection method (Zhang et al., 1999) in young F759 mice (2 months
old and arthritis free) and used the mice by the time they reached
4–5 months of age, because we have found that the clinical
scores of F759 mice normally show a significant difference
when the mice reach 6 months of age and that the clinical scores
of Il6/ F759 or Il17a/ F759 mice do not significantly differ
from those of control F759 mice when the mice are younger
than 4–5 months old (Figure 3A; Atsumi et al., 2002; Sawa
et al., 2006). As previously demonstrated, this treatment signifi-
cantly increased the serum concentrations of IL-6 (Figure 2C).
In fact, IL-17A overexpression induced arthritis in young F759
mice but not in control WT mice (Figure 3B and Figure S3A).
These results demonstrated that the arthritic condition that de-
Figure 3. IL-17A Is Critically Involved in the Development of Arthritis
in F759 Mice
(A) The clinical arthritis scores of Il17a/ F759 mice (filled circles, n = 17),
mean ± SD were determined by clinical assessment method of arthritis as
described in the Experimental Procedures and compared to Il17a+/ F759 or
F759 mice (open circles, n = 17).
(B) Two-month-old and arthritis-free F759 mice (mock, n = 12; IL-17A, n = 16)
or WT control mice (mock, n = 5; IL-17A, n = 5) were intravenously injected with
mock or IL-17A expression vector every 8–10 days, and the clinical score was
determined as described in the Experimental Procedures.
(C) Two-month-old and arthritis-free F759 mice (mock, n = 8; IL-17A, n = 8) or
WT control mice (mock, n = 4; IL-17A, n = 4) were intravenously injected with
mock or IL-6 expression vector every 8–10 days. They were then assessed for
signs of arthritis.
Data represent the mean ± SD (A) or SEM (B, C) of the scores. p values were
calculated with Student’s t tests. *p < 0.05; **p < 0.01; ***p < 0.005.velops in F759 mice is an IL-17A-mediated disease and strongly
supported the idea that enhanced IL-6 signaling driven by an
IL-17A-triggered positive-feedback loop is critical for the devel-
opment of arthritis in these mice.
To examine whether or not IL-6 is a critical downstream target
of IL-17A for the development of arthritis in F759 mice, we over-
expressed IL-6 via the hydrodynamics-based transfection
method in young F759 mice (2 months old and arthritis free)
and used the mice by the time they reached 4–5 months of
age. IL-6 overexpression resulted in the development of arthritis
in the young F759 mice but not in control C57BL/6 mice
(Figure 3C and Figure S3B) as was observed for IL-17A overex-
pression (Figure 3B and Figure S3A), although IL-6 overexpres-
sion did not markedly increase the serum concentrations of
IL-17A in the F759 mice (data not shown). These results indi-
cated that the enhanced IL-6 signaling contributes to arthritis
in F759 mice and suggested that IL-6 is a critical downstream
target of IL-17A during this process.
To examine the relative positions of IL-17A and IL-6 in this sig-
naling hierarchy directly, we used the two double mutant mouse
lines: Il6/ F759 mice and Il17a/F759 mice. We then overex-
pressed IL-17A and IL-6 in the Il6/ F759 and Il17a/ F759
mice, respectively; IL-6 expression induced arthritis in the
Il17a/ F759 mice, whereas IL-17A did not result in the develop-
ment of arthritis in the Il6/ F759 mice (Figures 4A and 4B and
Figure S3A and S3B). These data showed that IL-6 is a down-
stream target of IL-17A in the IL-17A-dependent arthritis that de-
velops in F759 mice. Taken together, the results show that excess
IL-6expression, which is induced by an IL-17A-triggered positive-
feedback loop, leads to an autoimmune arthritis in F759 mice.
IL-6–STAT3 Signaling in Fibroblasts Plays a Role
for the Development of Arthritis in F759 Mice
To investigate whether the F759 mutation in nonhematopoietic
cells is required for the development of the spontaneous arthritis,
Figure 4. IL-6 Is a Downstream Target of IL-17A in the Development
of Arthritis in F759 Mice
(A) Il17a/ F759, F759, or Il17a+/ F759 mice (2 months old and arthritis free)
were intravenously injected with mock (F759 mice, open circles, n = 12;
Il17a/ F759 mice, open triangles, n = 14) or IL-6 expression vector (F759
mice, closed circles, n = 14; Il17a/ F759 mice, filled triangles, n = 19) every
8–10 days, and assessed for signs of arthritis.
(B) Il6/ F759 and F759 mice (2 months old and arthritis free) were intrave-
nously injected with mock (F759 mice, open circles, n = 10; Il6/ F759 mice,
open triangles, n = 5) or IL-17A expression vector (F759 mice, closed circles,
n = 10; Il6/ F759 mice, filled triangles, n = 6) every 8–10 days, and assessed
for signs of arthritis.
Data represent the mean ± SEM of the scores. p values were calculated with
Student’s t tests. *p < 0.05; **p < 0.01; ***p < 0.005.Immunity 29, 628–636, October 17, 2008 ª2008 Elsevier Inc. 631
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mice by using the Cre-loxP system. The development of
arthritis was significantly suppressed in the type I collagen-
Cre-STAT3flox/flox F759 mice compared with controls (Figure 5).
These results showed that IL-6–STAT3 signaling, a component
of the IL-17A-triggered positive-feedback loop of IL-6 expres-
sion, in type I collagen+ fibroblasts is important for the develop-
ment of arthritis in F759 mice.
The IL-17A-Mediated Positive-Feedback Loop of IL-6
Expression Contributes to Enhanced Autoimmunity
in EAE
To determine whether the IL-17A-mediated positive-feedback
loop of IL-6 expression promotes and/or enhances autoimmu-
nity in WT mice, we performed several in vivo transfer experi-
ments in WT control mice by using pathogenic Th17 cells from
mice that had challenged EAE. We cultured CD4+ T cells from
EAE mice with bone marrow-derived dendritic cells in the pres-
ence of MOG peptide plus IL-23, resulting in IL-17A-producing
MOG-specific CD4+ T cells (Figure S4E). The transfer of Th17
cells induced EAE and increased the serum IL-6 concentration
in WT mice (Figure 6A). This result was consistent with the
IL-17A-mediated IL-6 expression contributing to EAE in WT mice.
To further examine this possibility, we transferred the Th17
cells into Il6/, type I collagen-Cre-STAT3flox/flox, or control WT
mice to examine the development of EAE. We showed that con-
trol animals developed EAE disease. Importantly, both Il6/ and
type I collagen-Cre-STAT3flox/flox mice showed at least partial
suppression of EAE after the Th17 cells were transferred (Figures
6B and 6C). These results showed that IL-6–STAT3 signaling in
nonhematopoietic cells (type I collagen+ cells) contributes to
Th17 cell-mediated EAE in WT mice. Additionally, we induced
Th17 cell development from Il17a/and control mice immunized
with MOG peptide by the same method. The percentages and
numbers of CD4+ T cells in the inguinal lymph nodes were similar
in Il17a/ and control mice immunized with MOG peptide on
day 11 (data not shown). The percentages and numbers of
CD4+ T cells expressing high amounts of CD44 as well as those
Figure 5. IL-6–STAT3 Signaling in Type I Collagen+ Fibroblasts
Contributes to the Development of Arthritis in F759 Mice
Clinical scores for arthritis in type I collagen-Cre-STAT3flox/flox F759 mice (filled
circles; n = 15) were determined as described in the Experimental Procedures
and compared to those in control type I collagen-Cre-STAT3flox/+ F759
and STAT3flox/flox F759 mice (open circles; n = 20). Data represent the
mean ± SEM of the scores. p values were calculated with Student’s t tests.
*p < 0.05; ***p < 0.005.632 Immunity 29, 628–636, October 17, 2008 ª2008 Elsevier Inc.of CD4+CD25+ cells among the CD4+CD44hi T cells were also
similar in these mice (Figures S4A–S4D). Importantly, the expres-
sion of IL-17F and IFN-gwere also comparable between Il17a/
and WT T cells cultured in vitro (Figures S4F and S4G), whereas
IL-17A was not detected in cultured CD4+ T cells from Il17a/
mice (Figure S4E). These results suggested that IL-17A defi-
ciency does not markedly affect Th17 cell development. Then,
we transferred the CD4+ T cells into WT mice and investigated
the development of EAE. We showed that a lack of IL-17A expres-
sion in Th17 cells attenuated the development of EAE (Figure 6D).
Together, the results shown in Figures 1 and 6 support the path-
ologic roles of the positive-feedback loop between IL-17A and
IL-6 signaling in EAE.
DISCUSSION
We found here that IL-17A together with IL-6 synergistically
increased IL-6 expression in MEF cells through NF-kB and
STAT3 signaling. Indeed, in vivo expression of IL-17A increased
Figure 6. The Positive-Feedback Loop between IL-17A and IL-6
Enhances EAE in WT Mice
(A) WT mice (n =10; 2-month-old C57BL/6 mice) were intravenously injected
with Th17 cells from WT mice with EAE. Serum IL-17A concentrations were
determined with ELISAs.
(B) Il6/ mice and WT mice (2 months old) were intravenously injected with
Th17 cells from WT mice with EAE. The clinical EAE scores of Il6/ mice (filled
circles, n = 5) were determined as described in the Experimental Procedures
and compared to those of WT mice (open circles, n = 12).
(C) Type I collagen-Cre-STAT3flox/flox and WT mice (2 months old) were intra-
venously injected with Th17 cells from WT mice with EAE. The clinical EAE
scores of type I collagen-Cre-STAT3flox/flox mice (filled circles, n = 3) were de-
termined as described in the Experimental Procedures and compared to those
of control mice such as STAT3flox/flox mice (open circles, n = 5).
(D) WT mice (2-month-old C57BL/6 mice) were intravenously injected with
Th17 cells from WT mice with EAE and Il17a/mice. The clinical EAE scores
of WT mice (filled circles, n = 7) injected with Th17 cells from Il17a/ mice with
EAE were determined as described in the Experimental Procedures and com-
pared to those of WT mice with EAE (open circles, n = 6).
Data represent the mean ± SEM of the scores. p values were calculated with
Student’s t tests. *p < 0.05; **p < 0.01.
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IL-17A-triggered positive-feedback loop of IL-6 expression is
present in WT fibroblasts. IL-17A and IL-6 also synergistically
induced the expression of various NF-kB target genes, including
KC, MIP2, and IkB-z. IL-17A mediated the expression of these
genes in a manner that was IL-6 dose dependent. Thus, these
results suggested that STAT3 may directly or indirectly interact
with NF-kB, as reported previously (Battle and Frank, 2002;
Hagihara et al., 2005; Yang et al., 2007).
We hypothesized that dysregulation of this feedback loop may
contribute to the development of various IL-17A- and IL-6-medi-
ated autoimmune diseases. We first selected F759 mice as an
animal model to examine the dysregulation of the loop and dem-
onstrated that the spontaneously developing arthritis in F759
mice is dependent on IL-17A: F759 mice lacking IL-17A showed
significantly reduced clinical arthritis scores, and overexpression
of IL-17A in young arthritis-free F759 mice induced the develop-
ment of arthritis. Importantly, overexpression of IL-17A did not
trigger arthritis in Il6/ F759 mice, whereas overexpression of
IL-6 induced the disorder in Il17a/ F759 mice, indicating that
IL-6 is a critical downstream target of IL-17A. Consistent with
this result, IL-17A expression greatly increased the expression
of IL-6 in F759 mice.
To detail the relationship between the enhancement of the
IL-17A-triggered positive-feedback loop of IL-6 signaling and
arthritis in F759 mice, we have performed several in vivo and
in vitro experiments, which led to the following findings: (1) the
serum IL-6 and IL-17A concentrations markedly increased in
an age-dependent manner in F759 mice compared to the
concentrations observed in WT mice; (2) IL-17A overexpression
produced a larger increase in the serum IL-6 concentration in
F759 mice than that in WT mice; and (3) IL-6 expression via the
IL-17A-triggered positive-feedback loop was enhanced in F759
MEF compared to WT MEF cells. Collectively, the data under-
score the central role of the enhanced signaling mediated
through the IL-17A-triggered positive-feedback loop of IL-6
expression in fibroblasts in the development of arthritis in F759
mice. In fact, specific deletion of the essential loop component
STAT3 in type I collagen+ fibroblasts suppressed the develop-
ment of arthritis in F759 mice. Because F759 mice lack SOCS3-
mediated negative feedback only in the gp130 signaling axis, it
is reasonable to speculate that specifically deleting SOCS3 in
nonhematopoietic cells would also increase the risk of autoim-
mune and/or inflammatory diseases. Consistent with this notion,
SOCS3 deficiency in liver cells increased the degree of liver fibro-
sis (Ogata et al., 2006), which likely mirrors NF-kB activation in fi-
broblasts. In other words, dysregulated NF-kB activation in type
I collagen+ fibroblasts may trigger the feedback loop to increase
IL-6 expression in F759 mice, in which IL-6-mediated STAT3
activation is already dysregulated. Consistent with this scenario,
we previously showed that transgenic expression of HTLV-1–
Tax, which activates NF-kB, enhanced the IL-6-dependent
development of arthritis in F759 mice (Ishihara et al., 2004). More-
over, viral IL-17A from herpesvirus saimiri was shown to activate
NF-kB and induce IL-6 production in fibroblasts (Yao et al., 1995).
These results suggest that viral infections, which stimulate the
NF-kB signaling pathway in fibroblasts, may result in an in-
creased risk for the development of autoimmune diseases by
triggering the positive-feedback loop controlling IL-6 expression.Considering the requirement of IL-6 for Th17 cell development
(Bettelli et al., 2007; Nishihara et al., 2007), upregulation of IL-6
expression may expand the Th17 cell population on one hand,
while also amplifying the IL-17A-triggered positive-feedback
loop. This hypothesis is supported by results showing that
both the number of Th17 cells and the serum IL-17A concentra-
tion were elevated in older F759 mice compared with WT control
mice. Therefore, we propose that two cell populations, type I col-
lagen+ fibroblasts and Th17 cells, are components of an IL-6 sig-
naling amplifier in vivo. Under normal conditions, the IL-6 ampli-
fier is controlled by several negative-feedback mechanisms,
which maintain homeostasis of IL-6 and IL-17A signaling. Under
pathological conditions, in which Th17 cells trigger an autoim-
mune disease, the IL-6 amplifier abnormally enhances signaling;
the dysregulated enhancement mediated by the amplifier may
be induced by dysregulated activation of NF-kB and/or STAT3
in fibroblasts via a variety of stochastic environmental and/or
genetic factors.
IL-17A is a member of cytokine subfamily and is highly homol-
ogous to IL-17F, a cytokine known to stimulate the NF-kB path-
way. Because IL-17A deficiency resulted in a lower but recogniz-
able arthritis in F759 mice, we hypothesized that IL-17F in
addition to IL-17A may contribute to disease development.
We found that IL-17F was barely detectable in F759 mice and
Il6/ F759 mice regardless of age, whereas it was present in
Il17a//F759 mice (data not shown). These results suggested
that, under specific conditions, IL-17F may be involved in the
development of autoimmune arthritis.
Numerous studies support strategies that target TNF-a for the
treatment of rheumatoid arthritis as well as other chronic autoim-
mune diseases (Feldmann and Maini, 2001). Moreover, TNF-a
acts in concert with IL-17A to induce IL-6 production (Awane
et al., 1999; Chen et al., 2003; Ruddy et al., 2004). Therefore,
TNF-a may also enhance the IL-6 amplifier proposed here. Con-
sistent with this idea, we observed that depletion of TNF-a in F759
mice partially but significantly inhibited the development of arthri-
tis (data not shown). In addition, TLR-mediated signaling is
known to induce IL-6 expression (Akira et al., 2001; Medzhitov
et al., 1997); for example, spontaneous arthritis develops in
SKG mice in response to pathogens, whereas the mice remain
healthy under specific pathogen-free conditions (Sakaguchi
et al., 2003). This pathogen response can be mimicked via zymo-
san, which triggers IL-6 release (Hata et al., 2004). It is possible
that IL-6 expression induced by TLR-mediated signaling triggers
the IL-6 amplifier especially in the presence of activation of Th17
cells via the pathogens. Thus, a number of factors, including such
cytokines as TNF-a and other IL-6 family cytokines, TLR-medi-
ated signaling, and soluble IL-6R, may act upstream of the IL-6
amplifier, which may explain why targeting IL-6 signaling shows
therapeutic efficacy in humans with rheumatoid arthritis (Nishi-
moto and Kishimoto, 2004).
It should be noted, however, that other mechanisms can in-
duce autoimmune diseases, because not all rheumatoid arthritis
patients respond to anti-IL-6R therapy and depletion of IL-6
does not universally suppress the development of autoimmune
diseases in experimental models. Indeed, recent data has
highlighted a critical role for IL-23 in generating pathogenic
Th17 cells, whereas IL-6 alone generates T cells that produce
both IL-10 and IL-17A (McGeachy et al., 2007), suggesting thatImmunity 29, 628–636, October 17, 2008 ª2008 Elsevier Inc. 633
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immune diseases. Thus, the mechanisms underlying the develop-
ment of autoimmune diseases are complex. Here we have shown
that dysregulation of an IL-17A-triggered positive-feedback loop
of IL-6 expression in fibroblasts, at least in part, drives the IL-17A-
mediated autoimmune arthritis observed in F759 mice.
It is important to show that this IL-17A-triggered positive-feed-
back loop of IL-6 expression in type I collagen+ fibroblasts medi-
ates other autoimmune diseases. Because it was reported that
a neuroinflammation induced activation of fibroblasts followed
by type I collagen expression in spinal cord (Okada et al.,
2007), we used EAE as another experimental model. In addition,
to exclude a possible involvement of IL-6 in Th17 cell develop-
ment in vivo, we employed a Th17 cell-transfer system to show
that the feedback loop may play a role in EAE in WT mice. Injec-
tion of established MOG-specific Th17 cells into WT mice
increased IL-6 expression, which was followed by encephalomy-
elitis, and IL-6 deficiency in the recipient mice attenuated the de-
velopment of EAE after Th17 cells were injected. Moreover, spe-
cific depletion of STAT3 in type I collagen+ fibroblasts attenuated
EAE development. Finally, depletion of IL-17A from the injected
MOG-specific Th17 cells at least partially suppressed the devel-
opment of EAE. Together, these results strongly support a role
for an IL-17A-triggered positive-feedback loop of IL-6 expres-
sion in nonhematopoietic cells in the development of EAE in
WT mice. Therefore, we hypothesize that the IL-17A-triggered
positive-feedback loop of IL-6 expression in nonhematopoietic




C57BL/6 mice were purchased from Japan SLC. The F759 mouse line carrying
a human version of gp130 (S710L) was established previously (Atsumi et al.,
2002; Ishihara et al., 2004; Sawa et al., 2006). IL-6-deficient mice were pro-
vided by M. Kopf (Max-Planck-Institute of Immunobiology, Germany), back-
crossed with C57BL/6 mice more than 10 times, and crossed with F759
mice. Type I collagen-Cre mice were provided by G. Karsenty (Baylor College
of Medicine, Houston, TX) and crossed with STAT3flox/flox mice that were pro-
vided by S. Akira (Osaka University, Japan) (Takeda et al., 1998). IL-17A-defi-
cient mice in a C57BL/6 background (Iwakura and Ishigame, 2006) were
crossed with F759 mice. All mice were maintained under specific pathogen-
free conditions according to the protocols of the Osaka University Medical
School. All animal experiments were performed according to the guidelines
of the Institutional Animal Care and Use Committees of the Graduate School
of Frontier Bioscience and Graduate School of Medicine, Osaka University.
Clinical Assessment of Arthritis and Histological Analysis
Mice were inspected and assessed for signs of arthritis as described previously
(Atsumi et al., 2002; Ishihara et al., 2004; Sawa et al., 2006). In some experi-
ments, knee joints were fixed in Bouin’s liquid and embedded in paraffin. His-
tological analysis was performed with sections stained with hematoxylin-eosin.
Cytokine Expression In Vivo
Mouse IL-6 and IL-17A genes were cloned into the pCAGGS vector. The
resulting vectors or mock vectors were intravenously injected (IL-6 vector,
1 mg in 2 ml; IL-17A vector, 50 mg in 2 ml) into mice every 8–10 days as
described previously (Zhang et al., 1999). Twenty-four hours after injection,
the IL-6 and IL-17A concentrations in serum after IL-6 and IL-17A vector injec-
tions were 40 ng/ml and 20 ng/ml, respectively, whereas the levels of these
cytokines did not significantly increase with mock vectors comparing to the
levels observed in untreated mice.634 Immunity 29, 628–636, October 17, 2008 ª2008 Elsevier Inc.Intracellular Cytokine Staining
The in vivo number of Th17 cells was determined as previously described
(Nishihara et al., 2007). In brief, T cells from spleen and lymph nodes were
stimulated with CD3 and CD28 antibodies in the presence of Golgi-plug (BD
Biosciences) for 6 hr. Intracellular IL-17A was labeled with IL-17A antibodies
after surface staining, fixation, and permeabilization.
Antibodies and Reagents
APC-conjugated anti-CD4 (BioLegend); FITC-conjugated anti-CD44 (eBio-
sciences); PE-conjugated anti-CD25 (eBiosciences), anti-IL-17A (eBiosciences)
or control-IgG2a (eBiosciences); PE-Cy5-conjugated anti-CD4 (BioLegend);
and biotin-conjugated anti-CD8 (eBiosciences), anti-CD19 (eBiosciences),
anti-I-A/I-E (BioLegend), or anti-NK1.1 (eBiosciences) antibodies as well as
streptavidin-conjugated Pacific Blue (Invitrogen) were used for cell staining.
ELISA
IL-6, IFNg, KC, MIP-2, IL-17A, IL-17F, and soluble IL-6R levels in serum or in
cell-culture supernatant were determined with ELISA kits (BD Biosciences,
eBiosciences, or R&D).
Flow Cytometry
For cell-surface labeling, 106 cells were incubated with fluorescence-conju-
gated antibodies for 30 min on ice. The cells then were analyzed with CyAn
flow cytometers (BeckmanCoulter) and the collected data were analyzed
with Summit software (BeckmanCoulter) and/or Flowjo software (Tree Star).
Cell Preparation and Stimulation
MEF cells from WT and F759 fetuses (14–15 days postcoitus) were prepared
as described previously (Sawa et al., 2006). NEMO-deficient MEF cells were
kindly provided by M. Pasparakis (University of Cologne), M. Saito, and S.
Akira (Osaka University, Japan). IkBz-deficient MEF cells were kindly provided
by M. Yamamoto and S. Akira (Osaka University, Japan). MEF cells were
plated in 6-well plates (23 105 cells/well) and stimulated with IL-6 plus soluble
IL-6R (20 ng/ml each) and/or IL-17A (50 ng/ml) for 24 hr after 2 hr of serum star-
vation. Human IL-6 (Toray), human soluble IL-6R (R&D Systems), and mouse
IL-17A (R&D Systems) were used for the experiments. For knockdown of
STAT3, MEF cells were transfected with specific siRNA (Sigma-Aldrich) with
GenePORTER transfection reagent (Genlantis) 48 hr before the cells were
stimulated with the cytokines. Cells were harvested, total RNA was prepared
for real-time PCRs, and cell-culture supernatant was collected for ELISA
assays.
Induction of Th17 Cell Differentiation and EAE Development
WT or IL-17A-deficient mice were injected with MOG(33-55) peptide (synthe-
sized by Sigma) in complete Freund’s adjuvant (Sigma-Aldrich) at the base of
the tail on day 0 followed by intravenous injection of pertussis toxin (List
Biological Laboratories) on days 0, 2, and 7. On day 11, CD4+ T cells were
then sorted with anti-CD4 microbeads (BD Biosciences). The resulting
CD4+ T cell-enriched population (2 3 106 cells) was cocultured with rIL-23
(20 ng/ml; R&D) in the presence of MOG peptide-pulsed bone marrow-derived
dendritic cells (53 105 cells) for 3 days. Cells (53 105 cells) were then injected
intravenously into sublethally irradiated (5 gray) recipients on day 0 followed by
intravenous injection of pertussis toxin on days 0, 2, and 7. The clinical score
used is described previously (Huseby et al., 2001). Surface markers for CD4+
T cells, such as TCR, CD4, CD44, and CD25, were examined with the Th17
cells. For cell-surface labeling, 106 T cells were incubated with fluorescence-
conjugated antibodies for 30 min on ice. We routinely detected more than
20% IL-17A+ cells and less than 2% Foxp3+ cells among the WT CD4+
T cells after culture (data not shown). Cytokine concentrations in supernatants
of cultured Th17 cells from IL-17A-deficient and WT control mice were deter-
mined with ELISAs.
Real-Time PCRs
A GeneAmp 5700 sequence detection system (ABI, Warrington, USA) and
SYBER green PCR Master Mix (Sigma-Aldrich) were used to quantify the levels
of IkBz mRNA, IL-6 receptor mRNA, and HPRT mRNA. Total RNA was
prepared from MEF cells with a GenElute Mammalian Total RNA kit (Sigma-Al-
drich) and DNase I (Sigma-Aldrich). The PCR primer pairs used for real-time
Immunity
IL-17 and IL-6 Signaling in Autoimmune DiseasesPCRs were as follows: mouse HPRT primers, 50-GATTAGCGATGATGAACC
AGGTT-30 and 50-CCTCCCATCTCCTTCATGACA-30; mouse IkB-z primers,
50-GTGGCAGGTAGAGCAGGAAG-30 and 50-CCACCTGAAAGGCACTCTGT-30;
and mouse IL-6 receptor primers, 50-ACAGTGTGGGAAGCAAGTCC-30 and
50-CCGTGAACTCCTTTGACCAT-30. The conditions for the real-time PCRs
were 40 cycles of 94C for 15 s followed by 60C for 60 s. The relative mRNA
expression levels were normalized to the levels of HPRT mRNA.
Statistical Analysis
Student’s t tests (two-tailed) were used for statistical testing between two
groups.
SUPPLEMENTAL DATA
Supplemental Data include four figures and can be found with this article online
at http://www.immunity.com/cgi/content/full/29/4/628/DC1/.
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